APRIL
11.4.2024 11:59:30 CEST | Business Wire | Press release
Building on the success of its first transformation plan, APRIL is embarking on a new phase in its development with the ambition of becoming a European leader of global stature in the design, distribution and management of insurance solutions and financial products. The Group is planning an ambitious growth cycle, both organic and external, which will take it to a turnover of more than €1 billion by 2027.
With sales of €630m by 2023, 20% of which will be generated outside France, the Spring 2023 strategic plan has enabled APRIL to return to its basics and achieve sustainable growth. Today, the Group is looking ahead to a new stage in its development and has set itself the target of exceeding €1 billion in turnover by 2027.
« In an extremely competitive international environment, one of the most successful insurance brokers is French! Our nearly 3,000 employees are proud to continue APRIL's history and are in action to expand our global footprint, for the benefit of our tens of thousands of partners and our millions of customers, whom we support and protect on a daily basis, » states Eric Maumy, CEO of APRIL.
Four cardinal points to guide the Group's development:
the spirit of conquest, customer delight, technological performance and talent.
The spirit of conquest to become a global consolidator
With its sustained growth, APRIL Group will further accelerate its development based on three principles:
- Organic growth in its traditional markets: health and personal insurance for individuals, professionals and businesses, health insurance for expatriates and property and casualty insurance (auto, 2-wheeler, construction, real estate and yachting).
- Diversification into new growth drivers, as the Group has already begun to do with savings and asset management, which have become the Group's 4th business line.
- Internationalisation in all its markets, starting with international health, with strong ambitions in Europe, the Middle East and Asia.
In terms of diversification and internationalisation, APRIL Group intends to step up its external growth momentum, as demonstrated by the two deals completed since the beginning of 2024 with leading French savings company DLPK and UK two-wheeler specialist Lexham Insurance.
This consolidation drive will naturally go hand in hand with APRIL’s ongoing commitment to defending the interests of customers, particularly in terms of access to quality healthcare for as many people as possible.
Enchanting partners and customers to reinvent the insurance experience
Having improved its Net Promoter Score by more than 20 points in 4 years, the Group wants to accelerate its efforts to improve the experience of its partners and customers, by focusing on 3 key areas:
- Enhancing its service approach (easier access to healthcare networks and to teleconsultation facilities, etc.);
- Improving its digital systems - from the underwriting process to self-care areas and conversational tools;
- Strengthening and continually training the teams in contact with customers and partners, to offer them the very best in technology and human relations.
A technological transformation that incorporates Data & AI
APRIL Group plans to invests €70 million in its digital and technological transformation by 2027 with a twofold aim :
- Capitalising on data and artificial intelligence, via iterative projects that will be carried out within the group in France and internationally across all business lines to identify the potential for creating value for employees, customers and partners;
- Continuing to strengthen cyber security in an environment of heightened threat to all economic players.
Providing employees with a unique experience to attract and retain talent
With an average of 400 new hires per year since 2020, APRIL Group has strengthened its team, in particular by recruiting talent in high-tension professions, notably digital technology within its APRIL X hub and customer relations.
With its ambitions raised to 2027, the Group plans to offer a structured and enriched employee experience based on 3 levers:
- Developing talent through the knowledge factory, which will include strengthening the APRIL University and launching an Apprentice Training Centre;
- Focusing on our employees, with several agreements on intergenerational dynamics and inclusion & diversity, as well as the relocation of the Group's head office to more modern, collaborative offices in Lyon (France);
- Greater sharing of value, with the opening of the capital to all the Group's employees worldwide from April 2024.
True to its roots in the social economy, the Group plans to fuel its sustainable growth with a positive and real impact in terms of CSR, in particular through its APRIL Foundation, which focuses on the contribution of behavioural sciences to health prevention and promotion.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240411952024/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
